dc.relation.reference | 1. L. W. General considerations. In: Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutic. 1970:1154.
2. Acrchibald L PL and Monnet D. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-5.
3. File TM, Jr. Overview of resistance in the 1990s. Chest 1999;115(3 Suppl):3S-8S.
4. Jones RN. The emergent needs for basic reseach, education, and surveillnce of antimicrobial resistance. Diagn Microbiol Infect Dis 1996;25:1-9.
5. Castiglia M, Smego RA, Jr. The global problem of antimicrobial resistance. J Am Pharm Assoc (Wash) 1997;NS37(4):383-7.
6. Emori TG, D.H. Culver, and T.C. Horan. National Nosocomial Infections Surveillance (NNIS) system: descrption of surveillnce methods. Am J Infect Control 1991;19:19-35.
7. Jones RN, S.A. Marshall, M.A. Pfaller, W.W.Wilke, R.J. Hollis, M.E. Erwin, M.B. Edmond, R.P. Wenzel, and the SCOPE Hospital Study Group. Nosocomial enterococcal bloodstream infections in the SCOPE Program: antimicrobal resistance, species occurence, molecular testing results, and laboratory testing accuracy. Diagn Microbiol Infect Dis 1997;29:95-102.
8. Voelker R. New group tracks hospital's drug-resistant bugs. JAMA 1996;275:177-8.
9. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997: A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control 1999;27(3):279-84.
10. Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998;42(7):1762-70.
11. Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC. SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001. Braz J Infect Dis 2004;8(1):25-79.
12. Bell J, Turnidge J. SENTRY Antimicrobial Surveillance Program Asia-Pacific region and South Africa. Commun Dis Intell 2003;27 Suppl:S61-6.
13. Sader HS, Sampaio JL, Zoccoli C, Jones RN. Results of the 1997 SENTRY Antimicrobial Surveillance Program in Three Brazilian Medical Centers. Braz J Infect Dis 1999;3(2):63-79.
14. Sader HS, Jones RN, Gales AC, Winokur P, Kugler KC, Pfaller MA, et al. Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). SENTRY Latin America Study Group. Diagn Microbiol Infect Dis 1998;32(4):289-301.
15. Lauderdale TL, Clifford McDonald L, Shiau YR, Chen PC, Wang HY, Lai JF, et al. The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000. Diagn Microbiol Infect Dis 2004;48(3):211-9.
16. MA. M. Epidemiology and clinical inpact of gram-negative sepsis. Infect Dis Clin North Am 1991;5(4):739-52.
17. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999;159(10):1127-32.
18. Lautenbach E, Patel J.B., Bilker WB, Edelstein P.H., Fishman N.O. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumonia: risk factors for infection and impact of resistance on outcome. Clin Infect Dis 2001;32:1162-71.
19. Virk A, Steckelberg JM. Clinical aspects of antimicrobial resistance. Mayo Clin Proc 2000;75(2):200-14.
20. Weinstein MP, Towns ML, Quartey SM, et al. The Clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997;21:584-602.
21. Pop-Vicas AE DAE. The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital. Clin Infect Dis 2005;40(12):1792-8.
22. Aurora E P-VaEMCDA. The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital. Clin Infect Dis 2005 (15 June);40.
23. Pop-Vicas AE, D'Agata EM. The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital. Clin Infect Dis 2005;40(12):1792-8.
24. Lucet JC CS, Decre D, Vanjak D, Macrez A, Bedos JP, et al. Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquistion. Clin Infect Dis 1996;22:430-6.
25. De Champs C, Rouby D, Guelon D, Sirot J, Sirot D, Beytout D, et al. A case-control study of an outbreak of infections caused by Klebsiella pneumonia strains producng CTX-1(TEM-3) beta-;actamase. J Hosp Infect 1991;18:5-13.
26. Paterson DL ML, Casellas JM, Ko WC, Goossens H, Von Gottberg A, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:437-8.
27. Wiener J QJ, Bradford PA, Goering RV, Nathan C, Bush K, et al. Multiple antibiotic-resistant Klebsiella pneumoniae and Escherichia coli in nurisng home. JAMA 1999;281:517-23.
28. Friedman ND KK, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002;137:791-7.
29. Siegman-Igra Y FB, Orni-Wasserlauf R, Golan Y, Noy A, Schwartz D, Giladi M. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis 2002;34:1431-9.
30. Schiappa DA HM, Matushek MG, Hashemi FN, Sullivan J, Smith KY, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996;174:529-36.
31. Blot S VK, De Bacquer D, Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis 2002;34(12):1600-6.
32. Pena C PM, Ricart A, Ardanuy C, Ayats J, Linares J, et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in intensive care unit. J Hosp Infect 1997;35:9-16.
33. Piroth L AH, Doise JM, Vincent-Martin M. Spread of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: are beta-lactamase inhibitors of therapeutic value? Clin Infect Dis 1998;27:76-80.
34. Rao GG. Risk factors for the spread of antibiotic-resistant bacteria. Drugs 1998;55(3):323-30.
35. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002;136(11):834-44.
36. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118(1):146-55.
37. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31 Suppl 4:S131-8.
38. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115(2):462-74.
39. Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003;9(5):412-8.
40. Bryant RE HA, Hood CE, Koenig MG. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med 1971;127:120-8.
41. Bryan CS RK, Brenner ER. Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antmicrobial therapy. Rev Infect Dis 1983;5:629-38.
42. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. N Engl J Med 1985;313(13):793-9.
43. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA 1997;277(6):488-94.
44. Ho M, Hsiung CA, Yu HT, Chi CL, Yin HC, Chang HJ. Antimicrobial usage in ambulatory patients with respiratory infections in Taiwan, 2001. J Formos Med Assoc 2004;103(2):96-103.
45. Goldberg D. The cephalosporins. Med Clin North Am 1987;71:1113.
46. Gantz NM BR, Berk SL, Esposito AL, Gleckman RA. Manual f clinical problems in infectious disease. Fourth edition. Chap. 74: Choosing a cephalosporin. 1999:410-4.
47. MacDonald KL CM, Hargrett-Bean NT, Wells JG, Puhr ND, Collin SF, Blake PA. Changes in antimicrobial resistance of Salmonella isolated from humans in the United States. JAMA 1987;11(258):1496-9.
48. Ackers ML PN, Tauxe RV, Mintz ED. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise. JAMA 2000;283(20):2668-73.
49. Ko WC LH, Chuang YC, Liu CC, Wu JJ. Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia. J Infect. 2000;40(3):267-73.
50. Weber JT ME, Canizares R, Semiglia A, Gomez I, Sempertegui R, Davila A, Greene KD, Puhr ND, Cameron DN, et al. Epidemic cholera in Ecuador: multidrug-resistance and transmission by water and seafood. Epidemiol Infect 1994;112(1):1-11.
51. van den Bogaard AE, Stobberingh EE. Antibiotic usage in animals: impact on bacterial resistance and public health. Drugs 1999;58(4):589-607.
52. Sharma H, Unicomb L, Forbes W, Djordjevic S, Valcanis M, Dalton C, et al. Antibiotic resistance in Campylobacter jejuni isolated from humans in the Hunter Region, New South Wales. Commun Dis Intell 2003;27 Suppl:S80-8.
53. Sullivan LM MJ, D'Agostino RB Sr. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 2004;23(10):1631-60.
54. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143(1):29-36.
55. Fabian Jaimes CA, Giovannii Ruiz, Jorge Cuervo, juan Botero, Gloria Velez, natalia Upegui, and faber Machado. Predicting Bacteremia at the Bedside. Clin Infect Dis 2004;2004(38):357-62.
56. Aloy Duch A, Espejo Arenas E, Mauri Pont M, Garcia Restoy E, Simo Sanahuja M, Bella Cueto F. [Bacteremia in the patient with liver cirrhosis. Prospective study of 61 episodes]. Enferm Infecc Microbiol Clin 1990;8(9):540-3.
57. Kuo CH, Changchien CS, Yang CY, Sheen IS, Liaw YF. Bacteremia in patients with cirrhosis of the liver. Liver 1991;11(6):334-9.
58. Mizuno R, Nishiyama Y, Shimizu S, Kitagawa M. [Clinical study on bacteremia in patients with liver cirrhosis]. Kansenshogaku Zasshi 1996;70(5):456-62.
59. Thulstrup AM, Sorensen HT, Schonheyder HC, Moller JK, Tage-Jensen U. Population-based study of the risk and short-term prognosis for bacteremia in patients with liver cirrhosis. Clin Infect Dis 2000;31(6):1357-61.
60. Graudal N, Milman N, Kirkegaard E, Korner B, Thomsen AC. Bacteremia in cirrhosis of the liver. Liver 1986;6(5):297-301. | en |